ArticleJournal of clinical medicine2020
Silver Sulfadiazine Eradicates Antibiotic-Tolerant
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Review
- Screening of FDA-Approved Small Molecules to Discover Inhibitors of theBiochemistry · 2026Article
- Association between postoperative silver sulfadiazine dressings and surgical site infection after skin cancer excision: an observational cohort study with historical controls.Frontiers in surgery · 2026Article
- Distribution and Antibiotic Resistance Characteristics of Pathogenic Bacteria in Chronic Wound Infections: A Five-Year Retrospective Study at a Tertiary Hospital.Infection and drug resistance · 2026Article
- Silver sulfadiazine in modern dermatology.Dermatology online journal · 2025Review
- Bioinspired Membranes with Silver Sulfadiazine and Piperine for Enhanced Cutaneous Permeability.ACS omega · 2025Article
- Skin Microbiome and Radiation-Induced Skin Injury: Unraveling the Relationship, Mechanisms, and Therapeutic Implications.International journal of molecular sciences · 2025Review
- Skin microbiota and diabetic foot ulcers.Frontiers in microbiology · 2025Review
- Bacteriophage Therapy on an In Vitro Wound Model and Synergistic Effects in Combination with Beta-Lactam Antibiotics.Antibiotics (Basel, Switzerland) · 2024Article
- Relative Abundance and Detection ofMicroorganisms · 2023Review
- Buruli Ulcer and Medical Geo-Microbiology.Infection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections are among the most frequent and challenging events in diabetic foot ulcers (DFUs). Pathogenic bacteria growing in biofilms within host tissue are highly tolerant to environmental and chemical agents, including antibiotics. The present study was aimed at assessing the use of silver sulfadiazine (SSD) for wound healing and infection control in 16 patients with DFUs harboring biofilm-growing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.